JP Morgan Reinstates Neutral on Blue Owl Cap, Announces $18.5 Price Target
$OWL
Investment Managers
Finance
JP Morgan analyst Kenneth Worthington reinstates Blue Owl Cap (NYSE:OWL) with a Neutral and announces $18.5 price target.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/24/2026 | $10.00 | Buy → Hold | Deutsche Bank |
| 12/11/2025 | $18.00 | Neutral | UBS |
| 12/10/2025 | $20.00 | Mkt Perform → Strong Buy | Raymond James |
| 7/28/2025 | Mkt Perform | Raymond James | |
| 5/20/2025 | $23.00 | Mkt Perform → Outperform | Keefe Bruyette |
| 2/24/2025 | $29.00 | Overweight | Barclays |
| 1/23/2025 | $30.00 | Buy | Citigroup |
Barclays downgraded Blue Owl Capital from Overweight to Equal Weight and set a new price target of $11.00
Deutsche Bank downgraded Blue Owl Capital from Buy to Hold and set a new price target of $10.00
UBS resumed coverage of Blue Owl Capital with a rating of Neutral and set a new price target of $18.00
S-8 - BLUE OWL CAPITAL INC. (0001823945) (Filer)
10-K - BLUE OWL CAPITAL INC. (0001823945) (Filer)
SCHEDULE 13G/A - BLUE OWL CAPITAL INC. (0001823945) (Subject)
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany Secured new debt facility, providing up to $
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Fundbox, a leading provider of embedded capital infrastructure for the small business economy, today announced the renewal of its existing credit facility with ATLAS SP Partners ("ATLAS"), the warehouse finance and securitized products business majority owned by Apollo funds, and the addition of funds managed by Blue Owl Capital ("Blue Owl"), a global alternative asset manager, as new lenders to the facility. The facility deepens Fundbox's long-standing partnership with ATLAS and marks the start of a new relationship with Blue Owl, further strengthening Fundbox's growing network of institutional capital providers. Together, these relationsh
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Blue Owl Technology Finance Corp. (NYSE: OTF) ("OTF" or the "Company") today announced financial results for its fourth quarter and year ended December 31, 2025. FOURTH QUARTER 2025 HIGHLIGHTS Fourth quarter GAAP net investment income ("NII") per share of $0.26Fourth quarter adjusted NII per share of $0.30(1)Dividends declared for the first quarter were $0.40 per share, representing an annualized dividend yield of 9.2%(2) based on net asset value ("NAV") per share as of December 31, 2025In connection with the listing, the Board of Directors (the "Board") declared five special dividends of $0.05 per share to be paid quarterly through September 2026NAV p
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
4 - BLUE OWL CAPITAL INC. (0001823945) (Issuer)
Greg brings over 30 years of experience advancing defined contribution strategy for global asset managers across the U.S. retirement landscape. NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE:OWL), a leading alternative asset manager, today announced the appointment of Greg Porteous as Managing Director and Head of Defined Contribution Retirement Solutions. In this newly created role, Porteous will spearhead Blue Owl's efforts to expand access to private markets and alternative investment solutions within defined contribution (DC) retirement plans across the United States. "We are thrilled to welcome Greg, whose three decades of experience in defined contrib
Blue Owl managed funds to purchase approximately $7 billion of PayPal "Pay in 4" loans originated in the U.S. over the next two years SAN JOSE, Calif., Sept. 24, 2025 /PRNewswire/ -- PayPal Holdings, Inc. (NASDAQ:PYPL) and Blue Owl Capital (NYSE:OWL), a leading alternative asset manager, today announced the execution of a two-year agreement under which funds managed by Blue Owl will purchase approximately $7 billion of buy now, pay later (BNPL) receivables originated by PayPal in the U.S. PayPal will remain responsible for all customer-facing activities, including underwriting and servicing, associated with its U.S. Pay in 4 BNPL products. Online consumer financing has been a strategic offe
Longtime Chief Financial Officer Kevin Gerlitz Retires After 16 Years at Sound Point Sound Point Capital Management, a credit-oriented investment manager overseeing approximately $43 billion in total assets, today announced the appointment of Dan Fabian as Global Chief Financial Officer, effective immediately. He succeeds Kevin Gerlitz, who is retiring after a distinguished tenure as the firm's long-serving Chief Financial Officer. "We're thrilled to welcome Dan to Sound Point," said Stephen Ketchum, Founder and Managing Partner of Sound Point Capital. "His deep expertise across the asset management landscape and proven ability to scale global investment platforms makes him an invaluabl
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany Secured new debt facility, providing up to $
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Blue Owl Technology Finance Corp. (NYSE: OTF) ("OTF" or the "Company") today announced financial results for its fourth quarter and year ended December 31, 2025. FOURTH QUARTER 2025 HIGHLIGHTS Fourth quarter GAAP net investment income ("NII") per share of $0.26Fourth quarter adjusted NII per share of $0.30(1)Dividends declared for the first quarter were $0.40 per share, representing an annualized dividend yield of 9.2%(2) based on net asset value ("NAV") per share as of December 31, 2025In connection with the listing, the Board of Directors (the "Board") declared five special dividends of $0.05 per share to be paid quarterly through September 2026NAV p
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Blue Owl Capital Corporation (NYSE:OBDC) ("OBDC" or the "Company") today announced financial results for its fourth quarter and year ended December 31, 2025. FOURTH QUARTER 2025 HIGHLIGHTS Fourth quarter GAAP net investment income ("NII") per share of $0.38Fourth quarter adjusted NII per share(1) of $0.36, consistent with the prior quarter of $0.36Dividends declared for the fourth quarter were $0.37 per share, representing an annualized dividend yield of 10.0%(2)Net asset value ("NAV") per share of $14.81, as compared with $14.89 as of September 30, 2025, driven primarily by credit-related markdowns on a small number of names, partially offset by accre
SC 13G/A - BLUE OWL CAPITAL INC. (0001823945) (Subject)
SC 13G/A - BLUE OWL CAPITAL INC. (0001823945) (Subject)
SC 13G/A - BLUE OWL CAPITAL INC. (0001823945) (Subject)